KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Deborah H. Telman as General Counsel for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.
In her new role, Deb will act as senior legal advisor to the Board of Directors, Chief Executive Officer and senior management and will be responsible for the company’s worldwide legal affairs, compliance and global environmental health & safety. She will join Organon from Sorrento Therapeutics where she served as Senior Vice President, General Counsel and Corporate Secretary leading the legal, compliance, human resource and quality functions. Deb has spent more than 20 years in senior executive roles at several global companies including Abbott, Johnson Controls and Boeing. She also brings deep experience in mergers and acquisitions, including a major pharmaceutical spinoff with Abbott at the time of its spin from AbbVie.
“Deb’s proven leadership, industry knowledge and expertise will serve Organon employees, customers and shareholders well,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Her counsel will help set the new company on a path to positively impact the lives of patients and improve public health.”
“I am very pleased and excited to have Deb join us and direct our legal, compliance and health and safety strategies at Organon,” said Kevin Ali, appointed chief executive officer of Organon. “Her experience and expertise will be fundamental in advancing Organon & Co.’s vision to be the world’s leading women’s health company.”
The appointment of the General Counsel marks another important milestone as Merck prepares Organon & Co. to operate independently. The spinoff transaction is on track for completion in the first half of 2021. For further information, please visit https://merck.unleashinggrowthpotential.com
About Merck
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
